Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00005974
DRKS00005974
Completed
未知

Randomized controlled clinical study for 3-D volumetric evaluation of two techniques for periimplant guided bone regeneration procedures - 3D GBR

niversität Zürich, Zentrum für Zahnmedizin, Klinik für Rekonstruktive Zahnmedizin0 sites27 target enrollmentJune 23, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsK08.1Loss of teeth due to accident, extraction or local periodontal disease

Overview

Phase
未知
Intervention
Not specified
Conditions
K08.1
Sponsor
niversität Zürich, Zentrum für Zahnmedizin, Klinik für Rekonstruktive Zahnmedizin
Enrollment
27
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 23, 2014
End Date
March 20, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversität Zürich, Zentrum für Zahnmedizin, Klinik für Rekonstruktive Zahnmedizin

Eligibility Criteria

Inclusion Criteria

  • •Patients in need of an implant therapy
  • •\- vertical dehiscence of 3mm or more
  • •\- good general health conditions

Exclusion Criteria

  • •Contraindications for implant therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical trial to evaluate 3D-printed denturesPreference for type of denturesOral Health
ISRCTN17073439niversity of Leeds18
Active, not recruiting
Phase 1
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic DiseaseMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-002310-31-DKIncyte Biosciences Distribution B.V.85
Active, not recruiting
Phase 1
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic DiseaseMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-002310-31-GBIncyte Corporation648
Active, not recruiting
Phase 1
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancer
EUCTR2017-002310-31-NLIncyte Corporation85
Active, not recruiting
Phase 1
Phase 3 Study of Pembrolizumab with and without Epacadostat as a second treatment after a platinum containing chemotherapy for recurring or metastatic bladder cancerRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic DiseaseMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-002310-31-FRIncyte Corporation648